文献速递淋巴瘤

来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始治疗的多中心2期研究5年随访

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
PubMed 文献 · Blood · 2018-09-04

报告来那度胺联合利妥昔单抗(LR)作为套细胞淋巴瘤(MCL)初始治疗的多中心2期研究5年随访。38例参与者中位年龄65岁,27例(75%)可评估患者完成≥3年治疗。中位随访64个月,3年无进展生存(PFS)和总生存(OS)分别为80%和90%,5年估计PFS和OS分别为64%和77%。

要点

  • LR方案作为MCL初始诱导和维持治疗,5年估计PFS为64%,OS为77%。
  • 维持期血液学不良事件包括无症状3/4级中性粒细胞减少42%、血小板减少5%、贫血3%。
  • 10例完成≥3年治疗且有样本的患者中,8例达到MRD阴性完全缓解。

核心结论

  • 来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始诱导和维持治疗,随随访时间延长继续显示持久缓解和可控的安全性。

研究设计与样本

  • 多中心2期研究,评估来那度胺联合利妥昔单抗作为套细胞淋巴瘤初始治疗。
  • 方案包括诱导和维持治疗,持续治疗直至疾病进展,3年后可选停药。
  • 共38例参与者,中位年龄65岁,MCL国际预后指数低、中、高危分别占34%、34%、32%。

主要发现

  • 36例可评估患者中27例(75%)完成≥3年研究治疗。
  • 中位随访64个月(范围21-78个月),3年PFS为80%,OS为90%;5年估计PFS为64%,OS为77%。
  • 维持期血液学不良事件包括无症状3/4级中性粒细胞减少42%、血小板减少5%、贫血3%。
  • 维持期感染多为1或2级,包括上呼吸道感染45%、尿路感染21%、鼻窦炎13%、蜂窝织炎11%、肺炎8%。
  • 10例完成≥3年治疗且有可用样本分析的患者中,外周血MRD检测(clonoSEQ)显示8例达到MRD阴性完全缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen includes induction and maintenance with the LR doublet. Treatment was continuous until progression, with optional discontinuation after 3 years. The median age of the 38 participants was 65 years, with MCL international prognostic index scores balanced among low, intermediate, and high risk (34%, 34%, and 32%, respectively). Twenty-seven (75%) of the 36 evaluable patients completed ≥3 years of study treatment. At a median follow-up of 64 months (range, 21-78), the 3-year progression-free survival (PFS) and overall survival (OS) were 80% and 90%, respectively, with 5-year estimated PFS and OS of 64% and 77%, respectively. During maintenance, hematologic adverse events (AEs) included asymptomatic grade 3 or 4 cytopenias (42% neutropenia, 5% thrombocytopenia, 3% anemia) and mostly grade 1 or 2 infections managed in the outpatient setting (45% upper respiratory infection, 21% urinary tract infection, 13% sinusitis, 11% cellulitis, 8% pneumonia). Nonhematologic AEs, such as constitutional and inflammatory symptoms, occurred at reduced frequency and intensity compared with induction. A peripheral blood minimal residual disease (MRD) assay (clonoSEQ) showed MRD-negative complete remission in 8 of 10 subjects who had completed ≥3 years of treatment and with available samples for analysis. With longer follow-up, LR continues to demonstrate durable responses and manageable safety as initial induction and maintenance therapy for MCL (ClinicalTrials.gov NCT01472562).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018. PMID: 30181173. doi:10.1182/blood-2018-07-859769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。